Hereditary spherocytosis
ESH eLearning, Alberto Zanella, 17962
Iron overload and chelation therapy
ESH eLearning, Maria Domenica Cappellini, 19866
Clinical cases
ESH eLearning, Maria Domenica Cappellini, 17961
Hereditary sideroblastic anaemias
ESH eLearning, Alison May, 17960
Rare inherited anaemias due to defects in the erythroblastiron acquisition pathway
ESH eLearning, Carole Beaumont, 17959
What are very rare anaemias ?
ESH eLearning, GULBIS BEATRICE, 17954
Welcome to Participants
ESH eLearning, Patricia Aguilar-Martinez, 19865
Recurrent fetal loss and thrombophilia
ESH eLearning, Saskia Middeldorp, 17339
Novel antithrombotic drugs
ESH eLearning, Sylvia Haas, 17338
Disseminated intravascular coagulation
ESH eLearning, Marcel Levi, 17337
Antiphospholipid syndrome
ESH eLearning, Ph G. de Groot, 17335
Cancer and thrombosis
ESH eLearning, Anna Falanga, 17334
Arterial thrombosis, pathogenesis, epidemiology
ESH eLearning, Gordon Lowe, 17330
Venous Thrombosis: etiology, pathogenesis and prognosis
ESH eLearning, Frits Rosendaal, 17328
Genetic risk factors of arterial and venous thrombosis
ESH eLearning, Pieter Reitsma, 17327
Control Mechanisms of coagulation
ESH eLearning, Bjorn Dahlback, 17326
Inherited platelet bleeding disorders, diagnosis and treatment
ESH eLearning, Alan Nurden, 17325
Management of coagulation disorders, complications and prevention
ESH eLearning, Pier Mannucci, 17323
Rare Bleeding Disorders
ESH eLearning, Flora Peyvandi, 17322
Molecular genetics of coagulation
ESH eLearning, Pieter Reitsma, 17320
Biochemistry of the coagulation systems
ESH eLearning, David Lane, 17319
Stopping TKI can now be recommended in selected partients: no
ESH eLearning, Giuseppe Saglio, 12583
Stopping TKI can now be recommended in selected patients: yes
ESH eLearning, François-Xavier Mahon, 12581
ESH eLearning, Session Speakers, 12606
Maintenance of a stable CCyR is an adequate therapeutic target: no
ESH eLearning, Philippe Rousselot, 12585
Maintenance of a stable CCyR is an adequate therapeutic target: yes
ESH eLearning, Michele Baccarani, 12584
All CML patients should start treatment with 2G-TKI: no
ESH eLearning, Charles SCHIFFER, 12586
Residual normal stem cells can be detected in newly diagnosed CML patients by a new flow cytometric approach and predict for optimal response to imatinib
ESH eLearning, Jeroen Janssen, 12601
The Prognostic significance of Molecular and Cytogenetic response landmarks after 3 month of Imatinib in the upfront treatment of CML
ESH eLearning, Benjamin Hanfstein, 12598
Switching to nilotinib vs imatinib dose escalation for patients with suboptimal treatment response to imatinib: 24 month update of the TIDEL-II trial
ESH eLearning, David T Yeung, 12596
High BCR-ABLIS expression levels at diagnosis and after 3 and 6 months of treatment are associated with an unfavourable response to imatinib
ESH eLearning, Paolo Vigneri, 12597
Correlation of hOCT1 genetic polymorphisms with the clinical outcome Athina Giannoudis (Liverpool) of CML patients treated with imatinib
ESH eLearning, Athina Giannoudis, 12595
BCR-ABL compound mutations in CML
ESH eLearning, Jamshid Khorashad, 12594
ESH eLearning, Session Speakers, 12604
JAK-2 is clearly an important therapeutic target in CML: no
ESH eLearning, Wolfgang Warsch, 12592
JAK-2 is clearly an important therapeutic target in CML: yes
ESH eLearning, MIN CHEN, 12590
There is a definite need to target stem cells: no
ESH eLearning, Giovanni Martinelli, 12588
CML . Reminiscences and dreams
ESH eLearning, John Goldman, 12532
Finding the soft spot: targeting CML stem cells
ESH eLearning, Mike Deininger, 12534
A novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance to tyrosine kinase inhibitors in CML stem/progenitor cells
ESH eLearning, MIN CHEN, 12535
BCL6 is required for the initiation and maintenance of CML
ESH eLearning, Christian Hurtz, 12536
Targeting of a novel MNK-eIF4E-b-catenin axis in blast crisis CML inhibits leukimia stem cell funcation
ESH eLearning, Sharon Lim, 12542
Evaluation of the efficacy and mechanism of action of the JAK2 inhibitor INCB18424 in primary CML stem/progenitor cells
ESH eLearning, Paolo Gallipoli, 12544
Inhibition of the PI3K/Akt/mTOR pathway induces cell death and protective autophagy in TKI-resistant CML cells
ESH eLearning, Gudmundur Vignir Helgason, 12547
A novel BIM polymorphism mediates resistance to BCR-ABL inhibitors in CML
ESH eLearning, King Pan Ng, 12550
Identification of novel kinase-activating rearrangements in BCR-ABL 1-like ALL by next generation sequencing
ESH eLearning, Kathryn Roberts, 12552
General Discussion
ESH eLearning, Session Speakers, 12553
Irreversibel apoptosis commitment of CML cells following acute exposure to tyrosine kinase inhibitors: oncogenic shock, cryptic intracellular retention or both?
ESH eLearning, Thomas O'Hare, 12556
Sensitivity to imatinib in BCR-ABL1-positive CML cells is regulated by remaining normal ABL1 kinase
ESH eLearning, Yashodhara Dasgupta, 12557
Keynote lecture: 10 years of imatinib resistance- heaps of mutations and a dozen new TKI : what we have learned . a biochemist.s view
ESH eLearning, Oliver Hantschet, 12558
Rac2 - mitochondrial respiratory chain complex III signaling generates reactive oxygen species causing genomic instability in CML-CP leukemia stem and progenitor cells
ESH eLearning, Piotr Kopinski, 12561
Targeting STAT5 in CML: Mechanism-of-action of JAK2 tyrosine kinase inhibitors in CML unmask a direct BCR-ABL/STAT5 axis
ESH eLearning, Wolfgang Warsch, 12562
Regulation of mature versus immature conformation of BCR-ABL
ESH eLearning, Yoshiro Maru, 12563
Man versus machine: a semi-automated platform for BCR-ABL QPCR
ESH eLearning, Jerry Radich, 12566
Distinct graft-vs-leukimic stem cell of early or delayed donor leukocyte infusions in amouse CML model
ESH eLearning, Yi-Fen Lu, 12570
The BELA trial: 18-month update on safety and clinical activity in patients with chronic phase CML treated with bosutirub (SKI-606) or imatinib
ESH eLearning, C Gambacorti, 12571
Updated phase 1 data on ponatinib, a pan-BCR-ABL inhibitor, in CML and other hematologic malignancies
ESH eLearning, Jorge Cortes, 12572
Multiple non-resistant low-level BCR-ABL1 mutations in CML patients after imatinib resitance predict poor response and high risk of new resistant mutations during the second-lin kinase inhibitor therapy
ESH eLearning, Susan Branford, 12574
A Phase 1 study of DCC-2036, an oral novel inhibitor of Abl kinase, in adult patients with Philadelphia Chromosome Positive (Ph+) CML including patients with T315I mutation
ESH eLearning, Jorge Cortes, 12578
How do we define the 'best' front-line therapy for CML and can we afford it?
ESH eLearning, Stephen O'Brien, 12579
Extract from film: Institut Universitaire d'Hématologie de l'Université Paris Diderot
ESH eLearning, Didi Jasmin, 8112
Keynote lecture: Expression of haemoglobin genes in 2011
ESH eLearning, Douglas Higgs, 6824
Epidemiology and prevention programmes on thalassaemia and sickle cell disease
ESH eLearning, Michael Angastiniotis, 6826
Prevention of Thalassaemia and Sickle Cell Disease: Antenatal diagnosis and pre-implantation diagnosis
ESH eLearning, Jan Traeger-Synodinos, 6823
Prevention of Thalassaemia and Sickle Cell Disease: Neonatal screening, epidemiological surveys
ESH eLearning, GULBIS BEATRICE, 6822
Clinical cases of Sickle Cell Disease
ESH eLearning, Swee Lay Thein, 6820
Clinical cases of Sickle Cell Disease
ESH eLearning, John Porter, 6821
Thalassaemia and Sickle Cell Disease: Pathophysiology, evaluation of iron overload (ferritin, biopsy, MRI), chelation
ESH eLearning, John Porter, 6819
Haematopoietic stem cell transplantation (HSCT) in haemoglobinopathies
ESH eLearning, Alina Ferster, 6817
Laboratory diagnosis of abnormal haemoglobins: Phenotype: Sickling tests, solubility, oxygen affinity, electrophoresis and chromatography, peptide analysis, fingerprinting, mass spectrometry, Genotype: DNA studies
ESH eLearning, Frederic Cotton, 6816
Haemoglobins with abnormal functions: pathophysiology, clinical findings, complications, therapeutic management, haemoglobin with altered oxygen affinity, haemoglobins M or unstable
ESH eLearning, Dimitris Loukopoulos, 6815
Frequent haemoglobin variants: Hb C, Hb E, Hb D. - Epidemiology, clinical findings, compound heterozygosities
ESH eLearning, Jacques Elion, 6814
Methodologies and laboratory diagnosis -2: Molecular biology
ESH eLearning, Patricia Aguilar-Martinez, 6813
Methodologies and laboratory diagnosis -1: Including: Basic methodology, standardization; The value of red cell indices. morphology, inclusion bodies, reticulocytes. Separation and quantification of haemoglobin fractions
ESH eLearning, Joan-LLuis Vives-Corrons, 6812
Sickle Cell Disease in the adult: Emerging complications and management
ESH eLearning, Swee Lay Thein, 6811
Sickle Cell Disease (SCD) in the young: Clinical presentation, clinical findings, management
ESH eLearning, Mariane de Montalembert, 6810
Clinical cases of thalassaemia
ESH eLearning, Maria Domenica Cappellini, 6809
[alpha]-thalassaemia: other forms - ATRX syndromes, . thalassaemia associated with myelodysplasia
ESH eLearning, Douglas Higgs, 6808
[alpha]-thalassaemia : Clinical findings, genetic basis, molecular aspects of disease , genotype / phenotype relationships
ESH eLearning, Douglas Higgs, 6807
ß-thalassaemia: Molecular defects, genotype / phenotype relationship
ESH eLearning, Swee Lay Thein, 6805
Structure, genetic control and synthesis of haemoglobin, classification of disorders of haemoglobin Thalassaemias and related disorders (. and . globin clusters)
ESH eLearning, Dimitris Loukopoulos, 6804
Closing comments
ESH eLearning, John Goldman, 5566
Musical interlude
ESH eLearning, Charles SCHIFFER, 5567
Welcome to Washington
ESH eLearning, John Barrett, 5728
Allogeneic stem cell transplantation in elderly patients: is it feasible and effective
ESH eLearning, Jane Apperley, 5242
Other MPN
ESH eLearning, Jean-Jacques Kiladjian, 5241
CML in the elderly
ESH eLearning, Philippe Rousselot, 5240
Treatment of CLL in the elderly
ESH eLearning, Vincent Levy, 5239
Prophylaxis and management of toxicities induced by novel agents
ESH eLearning, Michel Delforge, 5233
Indolent lymphoma in the elderly
ESH eLearning, Christian BUSKE, 5238
Monoclonal gammopathies and multiple myeloma diagnostic criteria and prognostic factors
ESH eLearning, Joan Bladé, 5230
Diffuse large B-cell lymphoma in the elderly
ESH eLearning, Hervé TILLY, 5236
Helping the patient : how to focus on the real problems after cancer treatment
ESH eLearning, François Pein, 5235
Special lecture: The caregiver of the older aged person
ESH eLearning, Dr. Lodovico Balducci, 5234
Are current concepts in the treatment of multiple myeloma useful in elderly patients?
ESH eLearning, Jean-Luc Harousseau, 5231
Treatment of multiple myeloma in the elderly
ESH eLearning, Thierry Facon, 5232
Biology and treatment of ALL in the elderly
ESH eLearning, A.R. Delannoy, 5229
Management of AML in the elderly
ESH eLearning, Claude Gardin, 5228
Biology of AML in the elderly
ESH eLearning, Aline Renneville, 5227
The role of iron chelation therapy in elderly patients with MDS
ESH eLearning, ROSE Christian, 5226

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings